Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Meningococcal vaccines.

N E Rosenstein1, M Fischer, J W Tappero

  • 1Meningitis and Special Pathogens Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. nar5@cdc.gov

Infectious Disease Clinics of North America
|April 17, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.

Clinical pharmacology and therapeutics·2015
Same author

Susceptibility to Buruli ulcer is associated with the SLC11A1 (NRAMP1) D543N polymorphism.

Genes and immunity·2006
Same author

Leptospirosis among patients presenting with dengue-like illness in Puerto Rico.

Acta tropica·2005
Same author

Etiology of pulmonary infections in predominantly HIV-infected adults with suspected tuberculosis, Botswana.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2003
Same author

Risk of Mycobacterium tuberculosis infection and disease among health care workers, Chiang Rai, Thailand.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2003
Same author

Impact of enhanced notification of tuberculosis laboratory results to minimise treatment delay, Chiang Rai Hospital, Northern Thailand.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2003
Same journal

Prevention and Control of Clostridioides difficile Infection for the Infectious Diseases Clinician.

Infectious disease clinics of North America·2026
Same journal

Infection Control Strategies to Prevent Emergence and Transmission of Resistant Gram-Negative Bacteria.

Infectious disease clinics of North America·2026
Same journal

Preventing the Spread of Tuberculosis in Health Care Settings.

Infectious disease clinics of North America·2026
Same journal

Threats to Success: Principles of Infection Prevention and Control in Health Care Settings, Part 2: Device and Pathogen Management.

Infectious disease clinics of North America·2026
Same journal

Ventilator-Associated Events: Surveillance and Prevention.

Infectious disease clinics of North America·2026
Same journal

Nosocomial Fungal Infections: Epidemiology, Control Strategies, and Prevention of Candida and Other Yeasts.

Infectious disease clinics of North America·2026
See all related articles

Developing new meningococcal vaccines is crucial for global disease control. Current vaccines have limitations, necessitating innovative approaches for broader, long-lasting protection against meningococcal disease.

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Current polysaccharide vaccines for meningococcal disease have limitations in efficacy, particularly in young children.
  • Protein-polysaccharide conjugate vaccines offer potential but face cost and accessibility challenges.
  • Outer membrane protein (OMP) vaccines show promise for serogroup B but are limited by antigenic variability.

Purpose of the Study:

  • To review the limitations of existing meningococcal vaccines.
  • To explore alternative vaccine development strategies.
  • To highlight the challenges in creating a universal meningococcal vaccine.

Main Methods:

  • Review of existing literature on meningococcal vaccines.
  • Analysis of the immunological responses to different vaccine types.

Related Experiment Videos

  • Discussion of the antigenic properties of Neisseria meningitidis.

    • Main Results:

    • Polysaccharide vaccines induce suboptimal immunity.
    • Conjugate vaccines are expensive and may not reach underserved populations.
    • OMP vaccines provide strain-specific protection due to antigen variability.

    Conclusions:

    • Novel vaccine approaches are needed to overcome current limitations.
    • A universal vaccine targeting common antigens across all serogroups is ideal.
    • Neisseria meningitidis's immune evasion mechanisms present a significant challenge for future vaccine development.